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ABSTRACT 27 
In June 2017, The National Institute of Allergy and Infectious Diseases, part of the 28 
National Institutes of Health, organized a workshop entitled “Pharmacokinetics-29 
Pharmacodynamics (PK/PD) for Development of Therapeutics against Bacterial 30 
Pathogens”. The aims were to discuss details of various PK/PD models and identify 31 
sound practices for deriving and utilizing PK/PD relationships to design optimal dosage 32 
regimens for patients. Workshop participants encompassed individuals from academia, 33 
industry and government, including the United States Food and Drug Administration. 34 
This and the accompanying review on clinical PK/PD summarize the workshop 35 
discussions and recommendations. Nonclinical PK/PD models play a critical role in 36 
designing human dosage regimens and are essential tools for drug development. These 37 
include in vitro and in vivo efficacy models that provide valuable and complementary 38 
information for dose selection and translation from the laboratory to human. It is crucial 39 
that studies be designed, conducted and interpreted appropriately. For antibacterial 40 
PK/PD, extensive published data and expertise are available. These have been 41 
leveraged to develop recommendations, identify common pitfalls and describe the 42 
applications, strengths and limitations of various nonclinical infection models and 43 
translational approaches. Despite these robust tools and published guidance, 44 
characterizing nonclinical PK/PD relationships may not be straightforward, especially for 45 
a new drug or new class. Antimicrobial PK/PD is an evolving discipline that needs to 46 
adapt to future research and development needs. Open communication between 47 
academia, pharmaceutical industry, government, and regulatory bodies is essential to 48 
share perspectives and collectively solve future challenges.  49 
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INTRODUCTION 50 
Nonclinical infection models are commonly used to characterize 51 
pharmacokinetic/pharmacodynamic (PK/PD) relationships for antibacterials and provide 52 
critical information for designing human dosage regimens (1). The discipline of PK/PD 53 
has been developing for several decades, and there is extensive evidence 54 
demonstrating that nonclinical infection models can predict clinical outcomes (1, 2). 55 
Since typical antibacterial drugs target the pathogen and not the host, the basic 56 
antimicrobial pharmacology and microbiology of the drug-pathogen interaction can be 57 
studied outside of the clinical setting. These insights can be assumed to hold true, in 58 
general, for drug-pathogen interactions that occur during infection of a human host (3). 59 
While there are many elements that cannot easily be studied outside the setting of a 60 
human infection, the insights gained from nonclinical infection models strongly support 61 
the rational design of optimal antibacterial dosage regimens for evaluation in future 62 
clinical trials. 63 
The goal of conducting nonclinical PK/PD infection models is, first and foremost, 64 
to elucidate exposure-response relationships, and to subsequently design and optimize 65 
dosage regimens. It is crucial to understand how drug concentration profiles at the 66 
primary infection site can maximize bacterial killing and minimize the emergence of 67 
bacterial resistance. Armed with this knowledge, dosage regimens can be designed to 68 
balance these goals while maintaining an acceptable level of safety in humans. 69 
Establishing exposure-toxicity relationships and identifying optimal regimens which 70 
account for between patient variability can greatly support achieving this balance (4, 5). 71 
 The existing armamentarium of PK/PD models is commonly employed to support 72 
these goals throughout the phases of drug development. Data from nonclinical PK/PD 73 
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models are indispensable for selecting the doses and regimens for patients, 74 
establishing susceptibility breakpoints, and ultimately refining clinical dosage regimens. 75 
The latter should reliably achieve PK/PD targets to maximize the probability that all 76 
patients will achieve efficacious drug exposures while limiting resistance development. 77 
In the current environment, it can be challenging or virtually impossible to find 78 
and recruit a sufficient number of patients (e.g. those with infections caused by 79 
multidrug-resistant pathogens) for multiple, large-scale clinical trials designed for 80 
inferential testing.  Consequently, there may be a heavy reliance on nonclinical PK/PD 81 
data to support and enhance the insights gained from human studies. These data also 82 
comprise an important element of regulatory submissions, as evidenced by guidelines 83 
published by the European Medicines Agency (6, 7).  For submissions to the Center for 84 
Drug Evaluation and Research that rely on limited clinical data, the importance of 85 
nonclinical PK/PD information is magnified, and nonclinical data packages need to be 86 
thorough to strongly support safety and efficacy in patients (8). 87 
Generating robust nonclinical PK/PD data was a key topic in the workshop 88 
sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) in June 89 
2017 entitled “Pharmacokinetics-Pharmacodynamics (PK/PD) for Development of 90 
Therapeutics against Bacterial Pathogens”. This review aims to summarize the 91 
information presented and discussed regarding nonclinical PK/PD models. Workshop 92 
participants came from across academia, industry and government, including the United 93 
States Food and Drug Administration (FDA) to provide a wide range of perspectives. 94 
Characterizing PK/PD for new drugs can be complex, and there is no single roadmap 95 
that can be applied for all drugs. In this review, we sought to provide guidance and 96 
considerations for designing, performing and interpreting studies to develop a robust 97 
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and informative nonclinical PK/PD package. Moreover, we aimed to put the roles of 98 
these models into perspective to design safe and effective dosage regimens for future 99 
clinical studies. 100 
 101 
IN VITRO PK/PD MODELS 102 
Static concentration time-kill (SCTK) assays are suitable screening tools for 103 
assessing drug structure activity and exposure-response relationships and for choosing 104 
informative drug exposures for subsequent dynamic infection model studies over longer 105 
treatment durations. SCTK studies are used to assess antibacterial activity and are 106 
typically performed over 24 (to 48) h. They use constant antibiotic concentrations and 107 
assume no or limited drug degradation; however, this should be experimentally 108 
confirmed, especially in studies with resistant strains. This experimental model can 109 
efficiently assess exposure-response relationships against the predominant bacterial 110 
population for antibiotic monotherapy and evaluate PD drug interactions for 111 
combinations. Further, SCTK studies can identify the rate of bacterial killing, help to 112 
define whether microbial killing is concentration- or time-dependent, identify antibiotic 113 
exposures that maximize bacterial killing and minimize regrowth, as well as evaluate the 114 
effect of the initial bacterial inoculum on antibiotic activity (9-11). Depending on the 115 
study objectives, viable counts on agar plates with and without the antibiotic can be 116 
utilized to determine the impact of drug exposure on both total and less-susceptible 117 
bacterial population(s) and identify whether regrowth is caused by less-susceptible 118 
bacteria (12-14). Results from 24 or 48 h SCTK studies may predict outcomes in the 119 
dynamic one-compartment (chemostat) or hollow fiber infection model (HFIM) for the 120 
first 24 to 48 h, but not at later time points.  121 
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The SCTK can efficiently assess a large number of treatment and control arms. 122 
Other advantages include its low cost and minimal equipment requirements; limitations 123 
include the use of constant drug concentrations and typically short treatment duration 124 
(24 to 48 h). The study duration can be extended to over one week, if needed, by 125 
replacing the medium with fresh (antibiotic-containing) broth every 24 h. For less stable 126 
drugs, small antibiotic doses can additionally be supplemented to offset degradation 127 
(15). Dynamic in vitro PK/PD models offer the additional capability of evaluating the 128 
effect of drug concentrations that change over time and can thereby mimic drug 129 
concentration profiles in humans. Dynamic systems include the one-compartment 130 
model (also called chemostat) and the two-compartment HFIM (16-20). To more 131 
precisely achieve PK/PD targets in these more labor-intensive dynamic infection 132 
models, it is often beneficial to perform arithmetic MICs using finer than 2-fold dilutions, 133 
particularly for higher MIC values (e.g. >0.5 mg/L) where the large incremental 134 
increases in test concentrations reduce the precision of the measurement (e.g. lower 135 
test concentrations have 2 to 3 significant figures while higher test concentrations only 136 
have 1). 137 
Dynamic one-compartment models. Chemostats are one-compartment, 138 
bacterial culture bioreactors with a typical culture volume of 100 to 250 mL. Fresh media 139 
is added continuously while culture contents are removed at the same rate to maintain a 140 
constant volume (16). Drugs are either administered directly as a bolus or infused (via a 141 
pump) into the bioreactor or as continuous infusion with the inflowing medium (Figure 142 
1). The chemostat can simulate drug concentrations changing over time following a 143 
single half-life to evaluate efficacy. This model can also assess dose fractionation by 144 
splitting the same daily dose into various dosing intervals. Moreover, chemostats can 145 
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simulate different durations of infusion and front-loaded regimens, for example (Table 1) 146 
(21-24). With the continuous replenishment of growth medium and nutrients, the one-147 
compartment system supports testing longer treatment durations for dose-range and 148 
dose-fractionation studies. This system can simulate the time-course of antibiotic 149 
concentrations for monotherapies and combinations to study bacterial killing and 150 
regrowth. 151 
Limitations of the chemostat include the potential for washout of bacteria and 152 
contamination of the media, particularly for studies with longer treatment duration. Most 153 
published studies have been conducted over 96 h or shorter (and often only over 24 h). 154 
Simulating concentration-time profiles for drugs with a short half-life in the chemostat 155 
results in washout of a considerable number of bacteria. The latter will cause the drug 156 
exposure needed for bacterial killing and resistance prevention to be underestimated, 157 
especially for slowly replicating bacteria or subpopulations. Filters can be used to help 158 
mitigate this issue but are not ideal due to clogging by bacteria (20, 25). Both washout 159 
of bacteria and incomplete oxygenation can lead to substantially lower maximum 160 
bacterial densities in the chemostat compared to those in SCTK and HFIM. Depending 161 
on the simulated half-life, bacterial waste products may accumulate over time in the 162 
chemostat. These features limit the ability of the chemostat to evaluate bacterial killing 163 
and resistance prevention at high bacterial densities and over long study durations. 164 
 Dynamic two-compartment models. In our opinion, the HFIM is the preferred 165 
and most capable in vitro model for evaluating PK/PD indices (26) and concentrations 166 
that best predict bacterial killing and resistance prevention (Table 1). The HFIM is a 167 
two-compartment system where bacteria are entrapped in the extra-capillary space of a 168 
hollow fiber cartridge that serves as a peripheral infection site (Figure 2). This system 169 
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can simulate virtually any time-course of drug concentrations for one or multiple drugs 170 
with the same or different half-lives (27-30). Multi-exponential profiles can be simulated 171 
by switching the pump rates at appropriate times (31). Bacteria are contained within the 172 
peripheral compartment of the hollow fiber cartridge, which completely prevents 173 
washout of bacteria. The cartridge has a large surface-to-volume ratio (32), providing 174 
optimized growth conditions for aerobic bacteria since bacteria are constantly exposed 175 
to fresh broth and oxygen, and waste products are continually removed (Figure 2). 176 
Thus, the maximum achievable bacterial density in the HFIM is usually over one order 177 
of magnitude higher compared with that in the SCTK assay. Due to these differences in 178 
growth conditions, the SCTK model tends to show an extensively attenuated bacterial 179 
killing at high compared to low initial inocula for some drug classes (9, 10, 33). This 180 
attenuation (i.e. an inoculum effect) tends to be less pronounced in the HFIM (34, 35), 181 
since bacterial replication is faster in the HFIM compared to SCTK at the same bacterial 182 
density (e.g. 108 CFU/mL). The clinical relevance of experimental inoculum effects is not 183 
fully understood; however, it has been shown in a mouse model that higher drug 184 
exposures are required to achieve stasis or 1-log10 killing against a higher (107 CFU/mL) 185 
compared to a lower (105 CFU/mL) inoculum of multiple Staphylococcus aureus strains 186 
for four classes of antibiotics (36).  187 
The HFIM offers the advantage that it can assess resistance prevention over 188 
typical antibiotic treatment durations for serious bacterial infections in patients (i.e. 189 
approximately 5 to 14 days). For slowly replicating bacteria such as Mycobacterium 190 
tuberculosis, studies can be extended to 28 days (37, 38) and longer, if needed. 191 
Moreover, the HFIM is the most capable and informative in vitro model for evaluating 192 
the efficacy of drug combination regimens, front-loaded dosage regimens and for 193 
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antibiotics with a short half-life, since there is no washout of the microbe (39, 40). The 194 
HFIM is further suitable for studies with highly communicable or virulent BSL-3 195 
pathogens (such as Mycobacterium tuberculosis, Bacillus anthracis, Burkholderia 196 
mallei, Burkholderia pseudomallei, Francisella tularensis, and Yersinia pestis), since the 197 
bacteria are contained in the HFIM cartridge (27, 41).  198 
Limitations of the HFIM include its relatively high cost, which is compounded by 199 
the single use of cartridges, and the more extensive effort required to plan, set-up, and 200 
execute studies. Some (lipophilic) drugs bind to HFIM components, which hinders their 201 
testing. Different hollow fiber materials (including cellulosic, polysulfone and 202 
polyvinylidendifluoride [PVDF]) are available to minimize binding, if needed (32). Given 203 
the molecular weight cutoff of HFIM cartridges, β-lactamase enzymes are entrapped in 204 
the extracellular space. For sub-therapeutic regimens which provide limited or no 205 
bacterial killing, β-lactamase enzymes may accumulate over time in the cartridge and 206 
degrade β-lactams (35). This is likely moderated by bacterial proteases that break down 207 
β-lactamase enzymes and can be mitigated by washing of the bacterial suspension 208 
before it is inoculated into the HFIM cartridge. Therefore, quantifying β-lactam 209 
concentrations in the extra-capillary space of the HFIM cartridge (Figure 2) is warranted 210 
for β-lactamase (over)-producing strains. This is also essential for high inoculum studies 211 
of resistant strains for highly permeable pathogens such as Escherichia coli and 212 
Klebsiella pneumoniae. These β-lactamase-producing strains can cause a rapid decline 213 
of the extracellular β-lactam concentration due to β-lactamase activity in the periplasmic 214 
space of bacteria, an issue which also applies to SCTK and chemostat studies.  215 
 216 
CONSIDERATIONS FOR DESIGN AND CONDUCT OF IN VITRO PK/PD MODELS 217 
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Strain selection. Robust PK/PD analyses require examination of multiple strains 218 
that should include one reference strain (e.g. a widely available ATCC strain), one 219 
susceptible and two less-susceptible clinical isolates; the latter may include one strain 220 
from an intensive care unit (ICU) patient and one strain from a non-ICU patient. Strains 221 
should be relevant for the clinical indication and study purpose; they should include 222 
different resistance mechanisms and a relevant (i.e. wide) range of susceptibility to the 223 
studied drug(s). Studies evaluating isogenic sets of strains can provide valuable 224 
information about the impact of a specific resistance mechanism. 225 
Furthermore, the chosen strains should represent the most common mutation 226 
frequency (MF), and strains with the lowest MF (i.e. strains with a small number of pre-227 
existing resistant mutants) should be avoided. This necessitates determining the MF for 228 
a range of strains; it is recommended to test at least 3 strains of a given bacterial 229 
species for this purpose. For strains with multiple bacterial populations of different 230 
susceptibility towards an antibiotic, the impact of these less susceptible populations on 231 
PK/PD relationships and targets may need to be evaluated (34, 42). Appropriate 232 
reference strains (such as ATCC strains) should be used throughout the research 233 
program to demonstrate reproducibility. Finally, if possible, the chosen strains should be 234 
virulent in animal models to support efficient translation to animal studies, and virulence 235 
should be confirmed before conducting HFIM studies. 236 
 Inoculum and mutation frequency. The initial bacterial inoculum needs to be 237 
relevant for the clinical indication and study purpose. A high inoculum with a total 238 
bacterial burden of approximately 108.5 CFU or greater (equivalent to 15 mL of a 239 
bacterial suspension at 107.3 CFU/mL in the HFIM) is typically used in studies that target 240 
ventilator-associated and hospital-acquired bacterial pneumonia (VABP/HABP) and in 241 
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resistance prevention studies (43). Experiments with a total bacterial inoculum lower 242 
than approximately 106 CFU (equivalent to 15 mL of a bacterial suspension at 104.8 243 
CFU/mL or lower) are usually not relevant for clinical indications. However, such low 244 
inoculum studies may be highly suitable to address mechanistic research questions on 245 
the rate of de novo formation of resistant mutants or on phenotypic tolerance of the 246 
predominant population (in absence of pre-existing mutants at initiation of therapy), for 247 
example. Knowing the MF for the tested antibiotic(s) is essential (14). By considering 248 
the expected number of resistant mutants in the initial inoculum, one can increase or 249 
decrease the probability of a resistant mutant being present or absent, depending on 250 
the study objectives. To assess suppression of amplification of pre-existing less-251 
susceptible mutants, the number of bacteria in the total system volume should be at 252 
least 1 log10 CFU higher than the inverse of the MF. This ensures that all treatment and 253 
control arms contain at least one pre-existing less susceptible mutant (with a probability 254 
of 99.9% for a 16-arm study, see useful formulas in the Supplementary Materials).  255 
Duration of therapy and resistance prevention. The study duration depends 256 
on the study objective. To determine the PK/PD index (e.g. AUC/MIC, Peak/MIC or 257 
T>MIC) that best predicts bacterial killing, short-term studies over approximately 1 to 3 258 
days may be sufficient; longer studies are required for slowly replicating bacteria and 259 
should consider the cell division time. These data can be used to determine the drug 260 
exposure required to achieve 1-log10 or 2-log10 reduction in bacterial burden, or 261 
bacteriostasis at 24 h and end-of-study. To assess the drug exposure and dosage 262 
regimens that suppress resistance amplification, the treatment duration should mimic 263 
the therapy duration for the intended clinical indication (usually at least 5 to 8 days). 264 
Some antibiotic classes show emergence of resistance more rapidly (21, 34), but 265 
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absence of resistance emergence over the first two days often does not correlate with 266 
resistance prevention over 10 days. Therefore, HFIM studies to evaluate resistance 267 
prevention often use 7, 10 or 14 days of treatment (28, 44). 268 
Drug stability. It is critical to evaluate drug solubility and stability under relevant 269 
conditions (e.g. solvents, media, storage and experiment temperatures, as well as 270 
durations consistent with those of the planned experiments) (45, 46). Many antibiotics 271 
are hydrophilic and soluble in water (47), but some have limited solubility and their 272 
concentrations may decrease over time due to (slow) precipitation. In addition, drugs 273 
may bind non-specifically to flasks, tubing, filters, and fibers; thus, it is important to 274 
assess whether these issues exist. 275 
Drug concentration profiles.  When available, protein binding and 276 
pharmacokinetic data from patients with an infection should be used to simulate the 277 
non-protein bound (or “free”) concentration-time course of drugs in plasma or, ideally, 278 
tissue exposures at the primary infection site for the intended clinical indication (e.g. 279 
lung epithelial lining fluid [ELF] for pneumonia). This is important because exposure 280 
profiles in patients may differ from those in healthy volunteers, and between patient 281 
variability in PK can be substantial in the critically ill. Of note, infection and the 282 
associated inflammation can alter drug exposure in ELF or cerebrospinal fluid (CSF) 283 
(48, 49) and some antibiotics have heterogeneous distribution across major tissues and 284 
organs. For example, polymyxin B accumulates in kidney (50) but less in lung (51). It is 285 
further important to understand and simulate non-protein bound (i.e. free) drug 286 
exposures that are relevant to the infection site. 287 
If an active metabolite contributes to the overall bacterial killing, both the parent 288 
and metabolite should be evaluated separately and the concentration-time profiles of 289 
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both compounds should be generated in vitro at the values found at the intended 290 
infection site in patients. This provides the most accurate characterization of bacterial 291 
killing and resistance prevention for antibiotics with an active metabolite. For prodrugs 292 
that are inactive and/or rapidly converted to the parent, such as tedizolid, ceftaroline or 293 
colistin methanesulfonate, the drug exposure and PK profile of the biologically active 294 
compound should be dosed in in vitro PD systems (52, 53) due to different formation 295 
rates in vitro and in vivo. 296 
Quantifying drug concentrations. Determining the time-course of achieved 297 
drug concentrations in dynamic PK/PD models is a best practice, both to validate the 298 
simulated PK profiles and provide observed data for analysis. This is an essential step, 299 
rather than relying solely on mathematically predicting the expected drug exposures. 300 
This is particularly important for intermittent dosing and complex dosage regimens (e.g. 301 
front-loading (40, 54)). Collecting these data allows correlation of actual drug exposures 302 
with the extent of bacterial killing and resistance suppression and may explain 303 
unexpected results.  304 
Drug concentrations should be quantified at multiple times per dosing interval, 305 
e.g. at approximately 30 min after the end of infusion (to allow for proper equilibration of 306 
the system), one to three intermediate samples, and a sample towards the end of the 307 
dosing interval. This sampling scheme should be adjusted for more complex regimens 308 
and repeated during multiple dosing intervals to confirm reliability of the dosing 309 
(including the syringe pump), performance of the peristaltic pump, and characterize 310 
attainment of steady-state (35). 311 
Quantifying bacterial populations. The impact of drug exposure on the total 312 
and less-susceptible bacterial population(s) should be assessed (12, 13, 27-31, 34) 313 
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when the study objective includes assessing resistance prevention. The importance of 314 
conducting these types of studies is described in the Supplemental Materials. Killing of 315 
the predominant bacterial population is usually determined by quantitative viable counts 316 
on antibiotic-free agar. In contrast, killing and amplification of less-susceptible bacterial 317 
population(s) is assessed by viable counting onto antibiotic-containing agar. Sub-318 
culturing should be done on agar containing the same antibiotic(s) used in a respective 319 
treatment arm; and for all antibiotics for the growth control. Agar containing 3x and 5x 320 
the MIC is commonly used; however, this choice depends on the initial (i.e. pre-321 
treatment) MIC and the step size of the MIC change (e.g. due to loss of an outer 322 
membrane porin [OprD] or up-regulation of an efflux pump) associated with relevant 323 
resistance mechanism(s). The MF can also guide selection of appropriate antibiotic 324 
concentration(s) in agar that should be between the MIC of the parent strain and that of 325 
the first-step mutant. To identify potential second- and third-step mutants with further 326 
decreased susceptibility, higher multiples of the MIC in agar can be used. For drugs 327 
with a large increase in the MIC of first-step mutants, higher multiples of the MIC or a 328 
fixed concentration in agar (e.g. 300 mg/L rifampicin for Pseudomonas aeruginosa) can 329 
be employed (55). Strains with high baseline MICs and combination therapy studies 330 
require special attention for selecting the most suitable antibiotic concentrations in agar 331 
to quantify less susceptible population(s) (56). 332 
For most antibiotics, enumerating colonies of sub-cultured bacteria after 24 h of 333 
incubation on antibiotic-containing agar is not sufficient and may greatly underestimate 334 
the less-susceptible population. Additional colonies may become visible after 48 to 72 h 335 
of incubation. Loss of moisture in agar can be minimized via a humidified incubator, 336 
increased agar volume per plate, or by incubating a tray of agar plates in a partially 337 
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opened plastic bag. Drug stability in the agar during incubation should be experimentally 338 
tested, especially for bacteriostatic antibiotics that inhibit growth but cause only slow 339 
bacterial killing. Moreover, the MICs should be determined for a subset of colonies 340 
growing on antibiotic-containing agar to validate their decreased susceptibility to the 341 
antibiotic. 342 
Data analysis approaches. Empirical and mechanism-based mathematical 343 
models both have their roles for analyzing in vitro PK/PD data. Empirical models (23, 344 
57-72) are efficient and typically analyze viable counts at the end of therapy, or the area 345 
under the viable count curve (on linear or log scale) during different time intervals (e.g. 346 
from 0 to 5 h, 0 to 24 h, and 0 h to end-of-study). Time-independent exposure-response 347 
relationships can identify exposure targets for efficacy and empirically describe the 348 
observed synergy of drug combinations; however, time-independent exposure-response 349 
analyses are not suitable to rationally optimize combinations or monotherapy regimens 350 
with changing dose intensity over time (e.g. front-loading), and do not describe the time-351 
course of drug concentrations. Empirical time-course models can describe drug-352 
concentration and viable count profiles, but lack mechanistic insights (e.g. receptors) 353 
and do not account for multiple resistance mechanisms. Particularly for combination 354 
therapy, empirical models cannot rationally optimize the effects elicited by antibiotics 355 
with multiple target sites or multiple mechanisms of action (10, 73, 74), or for 356 
combinations with several synergy mechanisms (14, 35, 75). 357 
Mechanism-based (MB) as well as Quantitative and Systems Pharmacology 358 
(QSP) models have been developed to overcome many of these limitations. While MB 359 
and QSP models both implement mechanism(s) of drug action, resistance or both, QSP 360 
models usually describe multiple different types of experimental observations to 361 
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characterize the mechanisms in more depth. Both of these models can simultaneously 362 
describe and predict the time course of bacterial killing and resistance emergence, and 363 
have been developed for antibiotic monotherapy and combinations (9, 10, 14, 15, 30, 364 
31, 33, 34, 40, 41, 55, 58, 71, 72, 76-84)(56). These models incorporate genotypic 365 
resistance development by multiple bacterial populations with different susceptibilities 366 
and phenotypic tolerance of slowly replicating bacteria. They offer the advantage of 367 
integrating molecular experimental data and allow rational optimization of innovative 368 
monotherapy and combination dosage regimens (including front-loading) for more than 369 
two drugs, if needed. Further, translational MB and QSP models can incorporate toxico-370 
dynamics (4, 5, 39, 85, 86) and account for the impact of the immune system (87-90). 371 
Independent of the approach employed, prospective experimental validation is essential 372 
(31, 72). 373 
Interpretation of results:  When interpreting in vitro PK/PD results, it is 374 
important to consider the mode of drug action; i.e. is the antibiotic rapidly or slowly 375 
killing, and which endpoint (e.g. stasis, 1-log10 or 2-log10 killing) is most clinically 376 
relevant. A stasis endpoint may be sufficient for less acute clinical indications such as 377 
uncomplicated skin and skin structure infections and complicated urinary tract 378 
infections. However, 1- or 2-log10 killing may be more desirable for severe infections 379 
(such as VABP). In addition, while the primary PK/PD index is often consistent between 380 
different pathogens and strains, the drug exposures required to achieve a target 381 
endpoint may vary greatly (91). This may have implications for translation to broad 382 
coverage and clinical utility of antibiotics (53, 92-94). Moreover, this reinforces the need 383 
to include a sufficiently diverse spectrum of bacterial strains in nonclinical PK/PD 384 
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models and to consider the potentially substantial between patient variability in PK, 385 
especially in unstable patients with sepsis or septic shock (see companion review). 386 
Potential extreme observations that fall outside of a predetermined threshold for 387 
an “outlier” (e.g. >2 SD from mean) should not be automatically discarded. Such data 388 
point(s) may represent an unexpected but important behavior (e.g. a mutation, with low 389 
frequency, leading to emergence of resistance; or development of tolerance to the 390 
drug). While mathematical approaches are available to handle potential “outliers”, 391 
experimental replicates and further laboratory investigation (such as characterization of 392 
resistant mutants and/or evaluation of potential drug tolerance) are strongly preferred. 393 
 394 
CHALLENGES OF INTERPRETING IN VITRO RESULTS 395 
The data generated using in vitro systems provide valuable insights into the 396 
direct interaction between the pathogen and the drug, and it is recommended that drug 397 
developers incorporate these types of models into their development programs. 398 
However, in some cases, the results may not directly translate to the clinic because in 399 
vitro systems do not fully mimic the in vivo environment. The PK/PD targets required in 400 
patients may be lower or higher than those in vitro if host factors affect bacterial killing 401 
or if the fitness of resistant mutants is reduced in vivo (95). An in vivo PK/PD target may 402 
be lower if the immune response contributes significantly to bacterial killing (3, 88); 403 
conversely, the in vivo target may be higher if host factors reduce the susceptibility of 404 
the bacteria (e.g. due to binding to lung surfactant, or persistence in deep seated or 405 
sequestered infection sites). Moreover, drug binding in plasma needs to be considered, 406 
since generally only free (i.e. unbound) drug is available to interact with bacterial 407 
receptors. Therefore, translation of PK/PD targets should be based on free drug 408 
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concentrations unless another rationale (e.g. for very highly bound drugs) is provided. It 409 
should be noted that in vitro studies generally do not incorporate plasma proteins (by 410 
design). Binding of many antibiotics to the in vitro pharmacodynamic systems is 411 
negligible (91), and the experiments inherently characterize free drug. This is in contrast 412 
to in vivo studies, in which results should be adjusted for protein binding in the test 413 
species. 414 
For emergence of resistance studies, it may be prudent to interpret results as an 415 
assessment of risk in the absence of host factors (e.g. the immune system), rather than 416 
as a direct prediction of clinical outcome. For example, while in vitro models are 417 
excellent for studying aminoglycosides as part of combination regimens (15, 31, 35, 55, 418 
56, 81, 96), they are not suitable for testing aminoglycoside monotherapy because this 419 
drug class readily generates small colony variants that are less common in vivo (10, 12, 420 
83, 95, 97). For these bacterial populations that cause failure of therapy in vitro, 421 
assessing the resistance mechanism(s), ability of high drug concentrations to kill these 422 
mutants, and the MIC-shifts towards potential partner antibiotics may be valuable. 423 
Further, evaluating synergistic drug combinations, as well as the in vivo fitness and 424 
virulence (98) may guide translation to animal models and ultimately to patients.   425 
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IN VIVO PK/PD MODELS 426 
Laboratory animal models have been used for decades to identify effective 427 
dosing regimens for clinical trials. Although dosages, drug clearance (including 428 
metabolism), and other factors often differ considerably between animals and humans, 429 
in vivo models play a critical role in characterizing the PK/PD for antibacterial agents 430 
(Figure 3). Animal models provide an in vivo infection environment and anatomical 431 
barriers that are difficult to reproduce in vitro. Animal infection models can forecast drug 432 
efficacy in patients, and the probability of regulatory approval increases with the 433 
probability of PK/PD target attainment (1, 2, 72, 99).   434 
The most widely used in vivo models for antibacterial PK/PD are the murine thigh 435 
and lung infection models (99). The thigh model is performed by injecting a bacterial 436 
suspension directly into the musculature of one or both thighs. The most commonly 437 
used lung infection model is performed by pipetting droplets of a bacterial suspension 438 
onto the nares and allowing the mice to inhale the inoculum. Both models often use 439 
cyclophosphamide-induced neutropenic mice to allow growth of a range of bacterial 440 
pathogens. Some bacterial strains can also produce robust infections in normal (i.e. 441 
non-neutropenic) mice, which provide information about the contribution of the immune 442 
response to the drug efficacy and may be better suited for studying resistance (which 443 
necessitates use of higher inocula). The primary endpoint is reduction of the bacterial 444 
burden in the infected tissue, which is typically assessed at 24 or 48 h after initiation of 445 
antibiotic therapy. Bacteriostasis, 1- or 2-log10 bacterial killing at 24 h (compared to the 446 
burden at the time therapy is initiated) is often used as an endpoint and has been 447 
shown to correlate with clinical outcome, including patients with infections such as 448 
hospital-acquired pneumonia, community-acquired respiratory tract infections, 449 
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bacteremia, and complicated skin and skin structure infections (1, 2, 99). Of note, 2-450 
log10 bacterial killing in mice at 24 h may not be achievable by slowly killing 451 
(‘bacteriostatic’) antibiotics. Considerable amounts of published data are available for 452 
many antibacterial agents in mice that can be used as positive controls; this presents a 453 
particular advantage of the murine neutropenic thigh and lung models compared to 454 
larger animal models. 455 
 456 
CONSIDERATIONS FOR DESIGN AND CONDUCT OF IN VIVO PK/PD MODELS 457 
Pharmacodynamic studies. Although the basic approach to conducting in vivo 458 
PK/PD studies is fairly standard, there is considerable variation among laboratories in 459 
the details of study design and conduct. These details can have a large impact on the 460 
results and should be carefully considered (101). Recommendations (Table 2) have 461 
been developed based on experiments that predicted clinical success (1, 2, 99), and 462 
this topic has been reviewed previously (100). Some recommendations may need to be 463 
adapted for specific drug-pathogen combinations or for other animal models. 464 
Benchmarking studies and the inclusion of comparator active control therapies to 465 
establish appropriate experimental conditions can enhance the utility of animal infection 466 
models and the robustness of predictions for translation to patients. 467 
Considering the number of mice per group is an important design choice for PD 468 
studies. It is difficult to provide explicit guidance on the number of animals required to 469 
appropriately power a study since it depends on a variety of factors (such as variability 470 
associated with a model, strain or drug; the number of groups within an experiment; and 471 
the type of analysis to be conducted). Sample sizes can be calculated for statistical 472 
comparisons of viable counts at the end-of-therapy via t-test or ANOVA statistics (see 473 
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Supplemental Materials). As these analyses only consider a single time-point, the 474 
resulting samples sizes are conservative (i.e. higher) compared to the sample size 475 
required for time-course analyses via population PK/PD modeling. The latter approach 476 
estimates treatment differences based on the time-course of viable counts at multiple 477 
sampling times. 478 
In practice, there are typically 4 observations collected for each group using the 479 
standard neutropenic thigh or lung infection models, and consideration should be given 480 
to studying both sexes. Of interest, when using the thigh model, many investigators 481 
utilize both thighs as independent samples (thus including only 2 mice per group). 482 
Although this reduces the overall number of animals required, it may not be a best 483 
practice since two samples from the same animal are not independent. We recommend 484 
that the design and conduct of studies be supported by prospective statistical or 485 
modeling analyses to ensure an adequate number of truly independent observations are 486 
obtained to appropriately power the experiment for the intended purpose. 487 
Plasma protein binding. In order to interact with its molecular target, a drug 488 
must be freely available (e.g. not bound to host proteins), and only unbound drug 489 
molecules can penetrate through the outer membrane porins of Gram-negative 490 
pathogens. Therefore, results from in vivo studies should be adjusted for protein binding 491 
and expressed in terms of free (f), i.e. non-protein bound, drug. It is recommended to 492 
conduct protein binding studies across a relevant concentration range with an 493 
appropriate in vitro assay. Whenever possible, at least 3 concentrations covering the 494 
anticipated in vivo plasma and tissue concentrations should be studied. A number of 495 
different in vitro assays are available. Currently, equilibrium dialysis is considered the 496 
reference method and is preferred over ultracentrifugation (101). The most accurate 497 
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measurements can be made using radiolabeled drug; however, this may not be possible 498 
in the early stages of development. Typically, a single protein binding value is 499 
determined (for example, an average across the concentrations tested) and all in vivo 500 
PK measurements are adjusted by multiplying the measured concentration by the 501 
assumed free percentage. If significant concentration-dependent binding exists, this 502 
nonlinear binding should be incorporated into the data analysis using mathematical 503 
modeling.  504 
Pharmacokinetic studies. Generating high quality PK data is critical for PK/PD 505 
analyses. The goal of PK experiments is to define the time course of drug 506 
concentrations in plasma, serum or blood, and potentially at the primary infection site. 507 
Several factors need to be considered for study design. As a best practice, exposure 508 
data should be collected from animals under the same conditions as the PD studies 509 
since infection may alter the PK (e.g. clearance and volume of distribution). If different 510 
matrices are collected across species (e.g. if drug concentrations are measured in 511 
whole blood for animal studies but in plasma for human studies), then red blood cell 512 
(RBC) partitioning needs to be determined and used to adjust for blood:plasma 513 
differences. Characterizing the PK at the infection site becomes comparatively more 514 
important for deep infection sites that equilibrate slowly or poorly with plasma and may 515 
be sequestered due to the infection (24, 48, 49, 102, 103).  516 
If a drug is being developed for treatment of bacterial pneumonia, it is 517 
recommended to utilize lung infection models for both PK and PD, and to determine 518 
lung epithelial lining fluid (ELF) concentration data. The latter is critical since the drug 519 
exposure profile at the infection site may substantially differ from that in plasma. The 520 
‘gold standard’ approach in both clinical and nonclinical studies is to characterize drug 521 
 o
n
 April 3, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
23 
 
concentrations in ELF, which is believed to represent the key compartment for infections 522 
by extracellular pathogens. Briefly, a bronchoalveolar lavage (BAL) is performed, and 523 
the BAL fluid is gently centrifuged to remove alveolar macrophages and other cells; this 524 
prevents bias in the ELF concentration, since some drugs accumulate extensively in 525 
these cells. Drug concentrations in the supernatant (i.e. diluted ELF) are measured and 526 
adjusted for the lavage dilution factor using the urea correction method (48, 104-107). 527 
This yields the drug concentration in the ELF. The cell pellet may also be utilized to 528 
determine concentrations within alveolar macrophages (104); these intracellular drug 529 
concentrations can be particularly important for some drugs (such as macrolides) and 530 
infections. 531 
For logistical reasons, systemic and/or tissue PK data are usually obtained 532 
separately in satellite PK experiments. A sufficient number of dose levels (usually 3 to 533 
4) are needed to identify and characterize non-linear PK, if present, and these should 534 
include the smallest and largest doses used in the PD studies to minimize extrapolation 535 
outside that range. The PK samples are typically collected via terminal procedures; 536 
thus, each animal usually contributes one concentration measurement at a single time 537 
point (especially in mice). Collecting serial blood samples from the same animal (e.g. 538 
multiple retro-orbital, facial vein or tail vein bleeds) at different time points better informs 539 
the PK parameters and allows one to separate between animal variability from residual 540 
error noise (e.g. bioanalytical noise). Serial blood sampling may not be possible in all 541 
infection models; however, methods have been developed and employed by some 542 
investigators (108-115).  Destructive sampling with one PK sample per mouse remains 543 
the most common approach.  544 
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Measuring drug concentrations in blood, plasma, and BAL (for ELF) can usually 545 
be accomplished via sensitive and specific LC-MS/MS assays. These are preferred over 546 
older bioanalytical methods (such as bioassays) because of their superior specificity, 547 
sensitivity and precision. Bio-active metabolites should also be measured and 548 
accounted for, if they are present at relevant concentrations. 549 
PK sampling times. Due to technical limitations and animal welfare 550 
considerations, there is a practical limit of approximately 6 to 8 sampling time points 551 
during any given experiment. Sampling times should be carefully chosen (and informed 552 
by any available PK data) to provide robust information within these experimental 553 
constraints. Studies should be designed and repeated, if necessary, to adequately 554 
capture information related to the absorption phase, peak concentration, drug 555 
distribution and elimination. Ideally, the chosen sampling times should reasonably 556 
characterize the overall drug exposure (i.e. the area under the curve, AUC), terminal 557 
half-life and the time when drug concentrations decline below the lowest MIC of interest.  558 
Mathematical modeling and simulation approaches (including optimal design 559 
methods) can be prospectively applied to select the most informative sampling time 560 
points  prior to conducting the PK experiment (116-120). If the design is suboptimal, the 561 
study may not provide adequate data to fully characterize the drug exposure profile. 562 
This is important because even the most sophisticated retrospective PK modeling and 563 
simulation approach will not compensate for poorly informative data; accuracy of PK 564 
predictions will suffer and ultimately, the calculated PK/PD targets may be biased. If no 565 
or insufficient prior PK data is available to aid in study design, a small pilot experiment 566 
may be warranted. Collection of high-quality PK data may require multiple, sequential 567 
experiments. This iterative process is considered best practice if a single experiment 568 
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does not adequately capture the PK profile. Although this approach may be complicated 569 
by factors such as limited time, resources and drug supply, it is imperative to collect 570 
suitably informative PK data.  571 
Studying drug combinations is more complex than evaluating monotherapies and 572 
requires additional consideration, such as potential drug-drug or drug-vehicle (e.g. for 573 
dimethyl sulfoxide, DMSO) interactions. Furthermore, it is important to assure that both 574 
drugs combined are present at the primary infection site at the same time. The design 575 
and interpretation of combination PK (and PD) studies benefits greatly from prospective 576 
application of mathematical modeling and optimal design approaches that are beyond 577 
the scope of this review (116-124). 578 
 Testing human-like exposures. The PK/PD index (e.g. fPeak/MIC, fAUC/MIC 579 
or fT>MIC) and its magnitude required for a chosen efficacy endpoint are typically 580 
determined using murine infection models. However, drug half-lives are usually much 581 
shorter in mice compared to those in humans (125), which results in concentration-time 582 
profiles with different shapes, even if both profiles are matched in the AUC. The 583 
importance of this aspect for bridging from animals to humans has been shown by 584 
Deziel et al. (126), where different dosage regimens were designed to achieve human-585 
like levofloxacin concentration-time profiles, but did not result in equivalent efficacy. 586 
Evaluating humanized PK profiles in animals can provide complementary information to 587 
traditional PK/PD indices and should be considered during drug development. 588 
Additional guidance on humanization (87) is provided in the Supplementary Materials. 589 
Analysis of PD data. To analyze viable bacteria count data (e.g. CFU at 24 h) at 590 
a single time point, a Hill model is commonly employed. Characterizing exposure-591 
response relationships (e.g. fAUC/MIC vs. effect) is strongly preferred over dose-592 
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response relationships (72), since the former account for PK and are thus much more 593 
informative. This basic PD approach is often useful for optimizing antibacterial 594 
monotherapy based on single time-point data. If multiple time points are evaluated (from 595 
different mice), population PK/PD modeling can characterize the time-course of 596 
bacterial killing and regrowth. Empirical, MB and QSP mathematical PK/PD models can 597 
be used to describe and predict the drug effect over time to rationally optimize dosage 598 
regimens as descried above for in vitro models. 599 
PK modeling approaches. Drug concentration profiles can be modeled by 600 
various approaches (127, 128), depending on the type of experimental data collected, 601 
the complexity of the results (e.g. linear vs. nonlinear PK), and the skillset of the 602 
modeler. For a typical dataset that contains one measurement per animal (e.g. terminal 603 
sampling at a single time-point), naïve pooling is often used. For this approach, all 604 
observations at a given dose are assumed to come from one animal. Alternatively, 605 
naïve averaging can be employed by calculating the average concentration at each time 606 
point. Both naïve approaches ignore between subject variability and only estimate one 607 
clearance and one volume of distribution for the pooled data. Estimates tend to be 608 
biased unless variability is small (e.g. coefficients of variation [CV] are less than 609 
approximately 15%) (127-129). To obtain standard errors for these datasets, the Bailer 610 
method (130, 131) and bootstrap re-sampling techniques have been developed (132-611 
134). The Bailer method uses linear combinations of mean concentrations at different 612 
time points to statistically compare the drug exposures between treatment groups. The 613 
bootstrap resampling approach randomly creates a number of pseudo-profiles to allow 614 
for statistical comparisons and estimate the between animal variability; this method is 615 
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very flexible and uses non-compartmental techniques for analysis of the pseudo-616 
profiles.  617 
If serial samples are obtained from the same animal, the standard two-stage 618 
method can be used where the data from each animal is fit separately. If each profile 619 
characterizes all PK phases (i.e. absorption, distribution and elimination), this method 620 
provides reasonable estimates of the mean PK parameters, but it may substantially 621 
over-estimate the variability between subjects (127, 128). Fitting the average plasma 622 
concentration profile via naïve pooling or the standard two-stage approach may be 623 
adequate to predict the mean concentration profile for datasets with small between 624 
subject variability.  This allows a broader range of scientists to perform PK modeling 625 
and to progress a drug development program efficiently. However, for datasets with 626 
large between subject variability, nonlinear PK, or multiple different types of 627 
observations (e.g. plasma, ELF, urine or efficacy data), population modeling offers 628 
substantial benefits. 629 
Population PK modeling. Population modeling borrows information across all 630 
subjects by fitting one subject in the context of all other subjects. This approach can 631 
simultaneously describe and predict exposure in multiple compartments, such as 632 
plasma and ELF (107, 135-138), and enables Monte Carlo simulations to predict the 633 
range of expected exposure profiles in patients (1, 14, 139). Population estimation 634 
algorithms have proven robust to estimate PK parameters both for frequently sampled 635 
and sparse datasets (129, 136) and are the method of choice for drugs with non-linear 636 
PK and for datasets with sparse sampling. This includes datasets with one plasma and 637 
ELF concentration per mouse. Population modeling is particularly powerful if advanced 638 
estimation algorithms based on the exact log-likelihood are employed. This approach 639 
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provides unbiased and precise estimates and predictions in a reasonable time frame 640 
considering the time for performing the experiments (Table 3) (129, 136, 140, 141). 641 
While full Bayesian approaches are appealing and powerful, they require more time 642 
(e.g. for sensitivity analyses) and advanced modeling skills (129, 142).  643 
 644 
CHALLENGES OF IN VIVO STUDY CONDUCT AND INTERPRETATION  645 
The success of characterizing PK/PD in animal models depends largely on sound 646 
experimental design, suitable data analysis, and the ability to control variance. This 647 
involves learning and refining in an iterative fashion to understand the sources of 648 
variability and then to minimize variance until the results converge around a final PK/PD 649 
target. This process benefits greatly from being executed by a close knit, highly 650 
functional team that regularly discusses experimental designs, results and 651 
interpretation. Several scenarios warrant special attention. 652 
Pharmacokinetic considerations: 653 
• Drugs with short half-lives in rodents can complicate study design (e.g. when the 654 
goal is to achieve a wide range of exposures in dose fractionation studies). 655 
• Species specific toxicities or PK profiles may hinder the ability to understand the full 656 
exposure-response (e.g. when sufficiently high doses to observe near-maximal 657 
effect cannot be tested). 658 
• Incorporating tissue concentration data may be complicated, yet it should not be 659 
assumed that the extent and rate of penetration is the same across animal species 660 
and humans. For pneumonia, approaches have been established and applied to 661 
design optimal dosage regimens based on ELF penetration data (48, 87, 104, 143, 662 
144). 663 
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• The time-course of penetration at the target site may not mirror circulating drug 664 
concentrations and may differ across species (e.g. for oritavancin; (103)). This may 665 
be particularly critical when maximizing synergy of drug combinations. 666 
• Plasma protein binding of drugs may differ between animals and humans and 667 
between ‘normal’ and critically-ill patients (145, 146). 668 
Pharmacodynamic considerations: 669 
• PD models are acute. Severe (often rapidly lethal) infections are usually required for 670 
model stability and minimizing variability, but this may not mimic the course of 671 
infections in humans. 672 
• Different PK/PD target values can be obtained from different models, studies and 673 
bacterial strains, as well as from various infection sites and/or test conditions. 674 
• Some studies and bacterial strains may not perform the same as others, even in 675 
well- characterized animal models; between strain variability is expected, and can 676 
complicate the establishment of PK/PD targets and subsequently human dose 677 
predictions. 678 
• Opinions vary on which endpoints should be used to establish PD targets (i.e. stasis 679 
vs. 1- or 2-log10 reduction in CFU; or alternatively using the doses associated with 680 
50% [ED50] or 90% [ED90] of maximal effect).  681 
• Different endpoints may be required for various types of infections and patient 682 
groups (e.g. for immuno-compromised patients or those with more serious infections 683 
such as VABP/HABP). 684 
• A more stringent endpoint such as 2-log10 reduction in CFU at 24 h in a mouse 685 
infection model may not be achievable for slowly killing antibiotics. Studies with 686 
longer treatment durations may be warranted to explore this situation. 687 
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Variability within and between studies. Variability associated with the conduct 688 
of animal infection models can be largely minimized via careful planning and execution. 689 
However, uncontrollable sources of variability associated with the PK, PD, infection site 690 
and immune response will remain and are difficult to control (Figure 4). This variability 691 
may lead to one or more extreme observations, and it can be tempting to remove such 692 
presumed “outlier(s)”. However, with the exception of a priori documented experimental 693 
reasons (such as those due to a missed dose), removal of outliers is not appropriate 694 
and will likely yield biased conclusions. Performing and presenting a data analysis with 695 
and without a ‘suspected’ outlier is good practice, as is the use of a suitable number of 696 
experimental replicates. If a whole experimental group (or entire study) appears to be 697 
an “outlier”, then a repeat evaluation is warranted. It is important to understand if such 698 
results are reproducible and to investigate why the results differ between replicated 699 
groups. 700 
It is common for results from studies conducted in different models or by different 701 
labs to vary to some degree and sometimes widely. In extreme cases, one set of results 702 
may support termination of a new drug candidate while another dataset for the same 703 
compound supports progression. It is likely that differences in the design, conduct and 704 
analysis of studies, even for the ‘workhorse’ murine PK/PD models, contribute to this 705 
situation. Careful experiment conduct is critical, and it may be helpful when using the 706 
‘workhorse’ models to standardize certain components such as inoculum size and 707 
preparation, strain fitness, timing of infection, infection site, inoculation method, and 708 
immune status. These variables can have a large impact on the results and conclusions 709 
(100). It is further helpful to benchmark PK/PD models and methods using relevant 710 
positive controls (i.e. effective reference treatments; Table 2 and Figure 5) for which 711 
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both animal and human PK/PD data are available for the target indication. By use of 712 
such active controls, a collection of data under standardized test methodology can be 713 
developed to support drug development and regulatory review. This will allow the 714 
performance of a new drug to be assessed in the context of benchmarked controls and 715 
endpoints.  716 
 Clinical dose selection. Guidelines have been published (e.g. by EMA) that 717 
recommend calculating PK/PD targets based on specific efficacy endpoints in the 718 
‘workhorse’ models for different clinical indications (6-8). In general, more antibacterial 719 
effect is required for more serious infections. Thus, targets based on no change in 720 
viable counts (stasis) or a 1-log10 reduction in CFU compared to pre-treatment baseline 721 
have been recommended for less severe infections such as skin and soft tissue as well 722 
as complicated urinary tract infections (cUTI); in contrast, 2-log10 reductions in CFU 723 
have been suggested for more severe infections such as pneumonia (43). Importantly, 724 
these endpoints are calculated relative to the bacterial density at initiation of antibiotic 725 
treatment, and not relative to the viable counts of the growth control group at end of 726 
therapy. The rationale for a higher 2-log10 hurdle is to rapidly reduce the bacterial 727 
burden to a density that can be controlled by the immune system; in the latter case, the 728 
surviving bacterial population is so small that the risk for emergence of resistance 729 
during therapy due to de novo formation of resistant mutants is low (1, 14). Although 730 
these are laudable goals, focusing on specified endpoints requires standardized model 731 
systems with benchmarking based on positive controls. Such highly-controlled animal 732 
infection models currently do not exist. 733 
Aiming for a stringent target endpoint (e.g. ≥ 2-log10 reduction in CFU) or the 734 
maximum tolerated dose is common in the early stages of clinical drug development. 735 
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High doses may help mitigate potential PK concerns, such as low drug exposure at the 736 
primary infection site, altered PK in special populations, and substantial variability in 737 
patients. However, almost invariably, the amount of drug that can be dosed in patients 738 
is limited by nonclinical safety coverage, clinical adverse events, lack of therapeutic 739 
index, cost-of-goods, and other factors. This typically leaves two options. First, drug 740 
developers can keep the same target endpoint and risk not covering the encountered 741 
MIC range; or second, a less stringent endpoint (e.g. stasis or 1-log10 reduction instead 742 
of 2-log10) could be used to set the target. The latter choice is the more common path, 743 
as not being able to cover the full MIC range is a poor starting point for a new drug and 744 
creates problems for establishing susceptibility breakpoints. However, use of less 745 
stringent endpoints may reduce the probability of achieving an adequate therapeutic 746 
response for more severe infections, can accelerate the development of resistance, and 747 
may result in breakpoints that are higher than appropriate. In this scenario, 748 
characterizing the impact of the immune system and, if mutants with reduced 749 
susceptibility are found, assessing their fitness in animals, as well as evaluating 750 
combination therapies for severe infections may be a path forward. 751 
Despite these complexities, the guiding principle should always be the scientific 752 
method, and there are steps that can provide additional confidence in the chosen 753 
nonclinical PK/PD targets and endpoints. It is best practice to generate data in more 754 
than one model system (i.e. another animal model and/or dynamic in vitro models). To 755 
enhance the information gained from the primary endpoint (e.g. reduction in CFU), 756 
secondary endpoints such as viable counts of resistant bacteria, biomarkers, survival, 757 
histopathology, inflammatory markers, radiology, bioluminescence, and others can 758 
provide valuable insights. Concerns may arise if discordant results are obtained from 759 
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different model systems and bacterial strains. However, this should not dissuade drug 760 
developers from conducting different types of experiments. Discordant results can be 761 
actively managed, explanations for the differences sought, and the insights gained can 762 
be highly valuable. 763 
 764 
Future perspectives on in vivo models.  765 
The field of antibacterial pharmacology is fortunate to have a considerable 766 
armamentarium of PK/PD tools and expertise. Commonly used models (such as murine 767 
neutropenic thigh and lung models) have provided a sound basis to-date. However, 768 
PK/PD is an evolving discipline, and challenges as well as open questions remain. 769 
Optimizing, standardizing and benchmarking the ‘workhorse’ models likely ensures 770 
better reproducibility from study-to-study and lab-to-lab, and enhances our ability to 771 
interpret the results for different types of infections and various antibacterial classes 772 
(Figure 5). Leveraging suitable modeling, simulation and optimal design approaches 773 
and engaging team members across disciplines to discuss feasible study designs, 774 
results and clinical goals is undoubtedly highly mutually fruitful.  775 
Establishing additional animal models for PK/PD characterization would expand 776 
translational tools available to the community. The murine thigh infection model 777 
reasonably mimics soft tissue infections, and the mouse lung infection model mirrors 778 
pneumonia. However, neither may be ideal for characterization of PK/PD at other 779 
infection sites. For lower urinary tract infections (e.g. cystitis), urine and/or bladder wall 780 
concentrations are likely important for efficacy. However, the mouse thigh model may 781 
not be adequate to determine reliable PK/PD targets for these infections, and other 782 
validated models do not (yet) exist. Similarly, there is a need for better models to 783 
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characterize PK/PD for complicated intra-abdominal infections (cIAI) and cUTI, 784 
especially since these are common target indications for Phase II studies. A rat model 785 
for cIAI is available (147, 148); however, some laboratories may not be able to conduct 786 
this model due to the increased complexity and animal species.  As a surrogate, the 787 
neutropenic murine thigh infection model can be a reasonable alternative for infections 788 
involving a rapidly equilibrating PK compartment such as pyelonephritis, where intra-789 
kidney concentrations are important; however, more data are required to fully assess 790 
nonclinical-to-clinical translation in these instances. Consideration should also be given 791 
to develop models that better mimic human disease (e.g. more natural disease 792 
progression), although such models are likely to be low throughput and less practical for 793 
routine PK/PD characterization. As one example, rabbit infection models have been 794 
developed and can provide serial blood samples for assessing PK and biomarkers of 795 
efficacy and safety over time (149-151). When combined with results from murine 796 
infection models, these more complex models could provide supporting information for 797 
new drugs and play an increasingly important role during drug development. 798 
A final point for consideration is publication of PK/PD data. It is important to 799 
provide sufficiently detailed information to allow readers to assess the validity of the 800 
work and resulting PK/PD targets, and to reproduce the methods employed. All 801 
pertinent details of the experiments (including detailed experimental protocols) and 802 
associated data analyses (including units, modeling choices and the enabling equations 803 
of the final model) should be published, at least in the supplementary materials. For 804 
common models and analyses, workshops with hands-on example datasets and (video) 805 
tutorials can provide effective training tools. Variability in PD response should be 806 
reported and details on the performance of individual bacterial strains (e.g. growth in 807 
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untreated control animals and variability of drug effect) and their individual PD targets 808 
provided. The PK data should be adequately described, and a thorough assessment of 809 
the quality of modeling and simulation methods provided (including an evaluation of bias 810 
and precision). It is suggested that editors consider both the ARRIVE guidelines (152) to 811 
ensure adequate reporting of in vivo data, as well as a set of extended criteria 812 
specifically for PK/PD studies to improve the quality of publications. Collections of 813 
resistant bacterial strains (e.g. from CDC and ATCC) are available, and future research 814 
and joint discussions are needed to select suitable reference strains. 815 
 816 
CONCLUSIONS 817 
Both in vitro and in vivo infection models provide powerful PK/PD information and 818 
have been shown to predict clinical outcomes. This review provides perspectives on 819 
current models, applications, challenges, potential issues and paths forward. This is a 820 
healthy and required evolutionary process to define and critique available methods. The 821 
goal is to improve approaches, models, study designs, study performance, analyses, 822 
interpretation and communication. Optimizing the available translational PK/PD tools 823 
has become increasingly important as we rely more and more on nonclinical data to 824 
predict successful clinical treatment regimens, often to combat serious infections by 825 
multidrug-resistant bacterial ‘superbugs’.  826 
Guidelines for conducting and interpreting nonclinical models are meant to 827 
improve the process, not to stifle innovation or eliminate the need for rational thought. 828 
Regular discussions among multi-disciplinary project teams are essential to optimally 829 
leverage these translational tools and early/frequent discussions with regulatory 830 
agencies are critical to maximize utility of the data. Future studies will likely identify 831 
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scenarios where the recommendations in this review will need to be modified for special 832 
infection models, bacterial strains, innovative combination regimens, and novel-acting 833 
therapies. Some therapies may require special considerations, and PK/PD approaches 834 
should be tailored to the specific needs of the individual compound or drug class and 835 
ultimately to the target patient population. 836 
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Figure 1: Dynamic one-compartment in vitro infection model (‘chemostat’). Fresh 1351 
media is added continuously while culture contents are removed at the same rate to 1352 
maintain a constant volume. A: Chemostat model for simulating a mono-exponential 1353 
decline of drug concentrations after intravenous dosing; antibiotic(s) are dosed into the 1354 
central reservoir as bolus doses or zero-order infusions. B: Chemostat for oral dosing 1355 
which can simulate drug concentration-time profiles with first-order absorption and 1356 
elimination; antibiotic(s) are dosed into the antibiotic reservoir as bolus doses or zero-1357 
order infusions. 1358 
 1359 
 1360 
  1361 
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Figure 2: Dynamic two-compartment hollow fiber in vitro infection model. A: Cross 1362 
section of a hollow fiber cartridge. Many hollow fibers provide a large surface area 1363 
(typically 0.2 to 0.3 m2, depending on the cartridge). According to the molecular weight 1364 
cutoff of the hollow fiber membrane, medium, drugs, oxygen, nutrients, bacterial 1365 
metabolites (‘waste products’) and other small molecules can exchange between the 1366 
central circulation (which includes the inside of the hollow fibers) and the extra-capillary 1367 
space of the cartridge. In contrast, bacteria, other cells (if present), and large molecules 1368 
are entrapped in the extra-capillary space of the hollow fiber cartridge. B: Flow of broth 1369 
medium from the fresh broth to the central reservoir. From the latter, broth is circulated 1370 
to the peripheral compartment (i.e. the extra-capillary space of the hollow fiber 1371 
cartridge) or is eliminated. Elimination occurs from the central into the waste broth 1372 
reservoir. A high precision dosing pump is used to dose drugs into the central 1373 
circulation. 1374 
 1375 
  1376 
 o
n
 April 3, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
51 
 
51 
 
Figure 3:  Overview of important variables which contribute to the outcome of animal 1377 
infection models. These factors may need to be considered for study design and 1378 
execution as well as for the data analysis and ultimate translation of rationally optimized 1379 
regimens to patients. 1380 
 1381 
 1382 
 1383 
 1384 
  1385 
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Figure 4:   Different sources of variability that may affect the results of animal 1386 
infection models. The between system variability can be handled by appropriate choices 1387 
for and the selection of experiments to be performed. The within- system variability can 1388 
be split into a controllable portion and a random (i.e. usually not-controllable) part. 1389 
Experimental design choices and careful execution of animal infection model studies 1390 
can minimize the controllable variability. The random, unexplained variability will 1391 
necessarily include components such as between subject variability (BSV) in 1392 
pharmacokinetics, pharmacodynamics, the infection site, and the immune system. 1393 
 1394 
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Figure 5  Considerations and perspectives to enhance the robustness of animal 1397 
infection models and ultimately better translate efficacious and reliable dosage 1398 
regimens to patients 1399 
 1400 
 1401 
 1402 
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Table 1.  Types of experiments that can be performed with widely used non-clinical 1404 
pharmacodynamic (PD) infection models. 1405 
 1406 
Study objective Static 
time-kill 
model 
One-compart-
ment system 
(‘chemostat’) 
Two-compart-
ment hollow 
fiber system 
Mouse 
infection 
model 
1.  Dose-range study: 
Killing of parent strain Yes
 a Yes a Yes a Yes a 
2.  Dose-range study: 
Suppression of resistance  +/- 
b +/- b Yes b +/- b 
3.  Dose-fractionation study:  
Killing of parent strain No Yes Yes Yes 
4.  Dose-fractionation study:  
Suppression of resistance +/- +/- Yes +/- 
5.  Combination therapy:  
Killing of parent strain Yes 
Yes (short 
term) Yes Yes 
6.  Combination therapy:  
Suppression of resistance No +/- Yes +/- 
7.  Toxin suppression by drugs Yes +/- Yes Yes 
8.  Dissecting the interaction of 
the parent drug and 
metabolites on antimicrobial 
effect 
+/- c +/- c Yes c No 
9.  Bacterial physiologic state & 
drug activity +/- +/- Yes +/- 
10. PD index for drug toxicity No 
No (unless 
toxicity is 
acute) 
Yes +/- d 
 1407 
+/-: Study objective can potentially be addressed in this system. 1408 
a: Bacterial strains which display the lowest mutation frequency of resistance should 1409 
be avoided in dose-range studies; instead strains which best represent the most 1410 
commonly observed resistance rates are preferred. 1411 
b: Strains with relevant resistance mechanism(s) should be chosen for in vitro studies. 1412 
The MIC50 and MIC90 for the pathogen of interest may be used to guide strain 1413 
selection. 1414 
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 1415 
c: Biologically active metabolite (s) need to be available, since they are most likely not 1416 
formed in the in vitro system. 1417 
d: Some dosage regimens (e.g. to assess time over a toxicity threshold) may also lead 1418 
to high peak concentrations, especially for short half-life drugs, which complicates 1419 
the interpretation of these studies. 1420 
 1421 
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Table 2. Recommendations for murine neutropenic thigh and lung infection models to 1423 
determine nonclinical in vivo PK/PD targets (data from Andes and Lepak 1424 
[100]) 1425 
 1426 
Study component Recommendationa Comments 
Mouse strain Outbred  
(e.g. CD-1, ICR or Swiss Webster) 
Historically female; studies in both 
sexes have been strongly 
encouraged recently and, if 
feasible, should be considered  
Induction of 
neutropenia 
Cyclophosphamide IP or SC at 150 
mg/kg at 4 days prior to infection 
and 100 mg/kg at 1 day prior to 
infection 
Results in neutrophils < 100 / mm3 
for at least 2 days. 
 
Inoculum 
preparation 
Culture should be in log growth 
phase 
Subculture aliquot from an 
overnight broth culture in fresh 
media for several hours prior to 
study start 
Mouse inoculation Infect thigh via IM injection of  
100 µL and lung via intranasal 
inhalation of 50 µL (i.e. 25 µL per 
nare) b 
Culture for inoculation should be 
106 to 107 CFU/mL 
Baseline bacterial 
burden 
106 to 107 CFU/tissue  
(may differ by pathogen and strain) 
Note that this represents the 
burden at the time therapy begins 
Start of therapy 2 h post infection Delay may be necessary for 
baseline tissue burden to reach 106 
to 107 
Study duration 24 h (sometimes 48 h) Post inoculation 
Bacterial growth 
over study period 
Tissue burden should increase by 
2-3 log10 CFU in untreated mice 
compared to baseline at initiation 
of therapy 
Note that this assumes the initial 
inoculum is sufficiently below the 
plateau for a given strain; less 
virulent strains may underestimate 
the PK/PD target  
Number of strains At least 4 strains of each target 
pathogen (including a reference 
strain), if possible, with relevant 
resistance profiles and 
mechanisms 
Include enough strains to assess 
strain-to-strain variability; mean 
and median PK/PD target values 
should converge 
Bacterial 
phenotypes 
Cover MIC range of compound, 
include clinically relevant resistant 
phenotypes 
Consider in vivo virulence when 
choosing strains 
Control therapies Inclusion of active comparator 
control (e.g. standard of care) may 
be beneficial. Dosage regimen 
(with/without humanizing) should 
be considered.  
Especially important for evaluation 
of combination therapies against 
multidrug-resistant strains. Dosing 
algorithm should be supported by 
PK/PD considerations. 
 1427 
CD-1: Outbred strain of albino mice  ICR: Outbred strain of albino mice. 1428 
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IP: Intraperitoneal     SC: Subcutaneous 1429 
IM: Intramuscular    CFU: Colony Forming Units 1430 
 1431 
a: These specific recommendations are for ‘routine’ establishment of PK/PD targets. 1432 
Study design elements may need to be modified to achieve different experimental 1433 
goals. Examples include the use of other bacterial phenotypes (including growth 1434 
stages), use of immune-competent mice (which can inform how targets may differ in 1435 
the presence of white blood cells and/or support longer treatment durations), and a 1436 
different bacterial burden (such as using a higher burden to study resistance). 1437 
b: The maximum volume of the bacterial suspension which can be given per nare will 1438 
depend on the mouse weight. This volume may affect the regional deposition of 1439 
bacteria in the lung. 1440 
  1441 
 o
n
 April 3, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
58 
 
58 
 
Table 3.   Comparison of PK modeling and simulation approaches in increasing order 1442 
of complexity from top to bottom. 1443 
 1444 
 1445 
Approach Between Subject 
Variability 
Accuracy of 
Predictions 
Comments 
Naïve 
pooling 
Ignored  
(i.e. assumed to 
be zero or very 
small) 
Only mean profiles  
can be predicted 
Can be adequate to simulate mean 
concentration profiles, if variability 
is small. 
Yields biased predictions if 
variability is moderate or large. 
Cannot simulate between subject 
variability. 
Standard  
two-stage 
Often 
overestimated 
Predicted 
concentration 
range may be too 
broad. 
Can be adequate to simulate mean 
concentration profiles, if variability 
is small. 
Requires serial sampling which 
may be problematic for mouse PK 
studies. 
Population 
modeling 
(approximate 
log-likelihood) 
Bias can be large 
for sparse data 
Can simulate 
variability, but may 
be considerably 
biased 
Can simulate mean concentration 
profiles and between subject 
variability, but may yield biased 
results for sparse data. 
Population 
modeling 
(exact log-
likelihood) 
Often most 
suitable choice 
Often most 
reasonable choice 
Can simulate mean concentration 
profiles and between subject 
variability with no (or less) bias. 
Can handle complex PK models 
with multiple dependent variables 
(e.g. PK, PD and resistance). 
Population 
modeling 
(advanced 
three-stage 
methods) 
Very powerful, 
can leverage prior 
information via a 
Bayesian 
approach 
Can account for 
uncertainty as well  
as between 
subject variability 
Powerful, but more complex; 
requires more expertise and 
modeling time (e.g. for sensitivity 
analyses). 
 1446 
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